Sofosbuvir/velpatasvir/voxilaprevir
| Combination of | |
|---|---|
| Sofosbuvir | NS5B RNA polymerase inhibitor |
| Velpatasvir | NS5A inhibitor |
| Voxilaprevir | NS3/4A protease inhibitor |
| Clinical data | |
| Trade names | Vosevi |
| AHFS/Drugs.com | vosevi |
| Routes of administration | By mouth (tablets) |
| ATC code | |
| Identifiers | |
| KEGG | |
Sofosbuvir/velpatasvir/voxilaprevir (trade name Vosevi) is a combination drug for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C virus: sofosbuvir, velpatasvir, and voxilaprevir.
Vosevi was approved by Food and drug administration in July 2017[1] and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[2] Vosevi is sold by Gilead Sciences.
References
- ^ "FDA approves Vosevi for Hepatitis C". fda.gov. Retrieved 2017-12-27.
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.